Abstract
Impact of baseline characteristics on the efficacy of ixekizumab in patients with moderate to severe psoriasis in a phase 2 study
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
